Add BrightSurf on Google Email

Tuberculosis: Scientists develop novel drug candidate for combating resistant pathogens

Researchers at Martin Luther University Halle-Wittenberg have developed a promising new substance that inhibits the ability of tuberculosis bacteria to produce energy and causes them to die. The compound, PRP020, targets the pathogen's ATP synthase but attacks a different site than existing drugs like bedaquiline.

SourceMartin-Luther-Universität Halle-Wittenberg·JournalJournal of Medicinal Chemistry·TypeExperimental study·DateDec 8, 2025

Antipsychotic medication use by older adults

A growing trend of antipsychotic medication prescription increases in older U.S. adults, with long-term care pharmacies being a primary source. Non-psychiatrist prescribers contribute to the trend, highlighting concerns over medication accessibility and oversight.

SourceJAMA Network·JournalJAMA Psychiatry·DateDec 3, 2025

Breakthrough pediatric kidney therapy emerges from U. Iowa research

Researchers at the University of Iowa Health Care have developed a new class of medication, pegcetacoplan, which directly targets the root cause of C3 glomerulopathy, a rare and severe kidney disease. The treatment has shown significant results, with up to 67% of children achieving complete remission and stabilization of kidney function.

SourceUniversity of Iowa Health Care·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 3, 2025

Long-term antidepressant use surges in Australia, sparking warnings of overprescribing

A new study found that long-term antidepressant use has increased by nearly 20% among young people aged 10-24, raising concerns about potential overprescribing. The study also found no meaningful improvement in efforts to wean patients off antidepressants, highlighting the need for a stronger framework for safely tapering medications.

SourceUniversity of South Australia·JournalPharmacoepidemiology and Drug Safety·TypeData/statistical analysis·DateDec 2, 2025

Behind the 2025 “shroom boom” hides a bad trip

The article highlights the mismatch between psychedelics and economic drug development principles. Pharmaceutical companies are developing short-acting compounds and neuroplastogens to engineer trips out of the experience altogether. Dr. Sandy Hager's research suggests investors should remain cautious due to weak intellectual property ...

SourceCity St George’s, University of London·JournalFinance and Society·TypeData/statistical analysis·DateNov 20, 2025

Healing the heart after a heart attack

A new patch developed by Texas A&M University researcher Dr. Ke Huang may offer a way to help the heart heal after a heart attack by delivering interleukin-4 directly to damaged heart tissue. The patch uses a microneedle system to promote repair and improve heart function without affecting the rest of the body.

SourceTexas A&M University·JournalCell Biomaterials·DateNov 19, 2025

Muscle protein linked to exercise opens new way to treat Alzheimer’s

Researchers at Florida Atlantic University have discovered a potential new treatment for Alzheimer's disease by targeting muscle protein Cathepsin B. The study found that increasing Ctsb in muscle tissue may offer protection against the effects of AD and promote brain cell growth, restoring protein balance and rebalancing brain activity.

SourceFlorida Atlantic University·JournalAging Cell·TypeExperimental study·DateNov 18, 2025

New molecule reduces ethanol intake and drinking motivation in mice, with sex-dependent differences

A new compound MCH11, a monoacylglycerol lipase inhibitor, shows promising effects in reducing alcohol consumption and motivation to drink in mice. The molecule exhibits anxiolytic and antidepressant properties with sex-dependent efficacy, correcting genetic alterations associated with alcohol use disorder.

SourceUniversidad Miguel Hernandez de Elche·JournalBiomedicine & Pharmacotherapy·TypeExperimental study·DateNov 11, 2025

Weight loss drugs don’t increase the risk of pancreatitis or adverse cardiac events in patients with high triglycerides

Researchers from Intermountain Health have found that GLP-1 receptor agonists do not increase the risk of pancreatitis or adverse cardiac events in patients with high triglycerides. Patients taking these medications had a four times lower risk of developing pancreatitis compared to those not on the medication.

SourceIntermountain Healthcare·TypeObservational study·DateNov 9, 2025

Practice pattern of aerosol drug therapy in acute respiratory distress syndrome patients: An aero-in-ICU study

The study highlights the frequent use of aerosol therapy in critically ill patients with acute respiratory distress syndrome (ARDS), with bronchodilators being the most commonly prescribed drugs. However, the lack of sound scientific evidence and randomized controlled trials suggests that standardized protocols are needed to align clin...

SourceJournal of Intensive Medicine·JournalJournal of Intensive Medicine·TypeObservational study·DateOct 29, 2025

Home treatment with IV antibiotics could relieve NHS pressure

A University of East Anglia study found that treating patients at home with IV antibiotics can save the NHS over £3,500 per patient and potentially free-up vital hospital beds. The treatment involves having antibiotics prepared at home and continuously delivered into the bloodstream by an elastomeric pump.

SourceUniversity of East Anglia·JournalJournal of Clinical Pharmacy and Therapeutics·TypeObservational study·DateOct 28, 2025

Exploring a mechanism of psychedelics

Scientists found that activating specific neurons in the claustrum region of male rats under psychedelic exposure strengthens connections to areas implicated in psychiatric diseases, potentially explaining how psychedelics improve memory and symptoms. The study suggests a new pathway for understanding psychedelics' therapeutic effects.

SourceSociety for Neuroscience·JournaleNeuro·DateOct 27, 2025

Group creates tool to predict whether multiple sclerosis medication will be effective for patients

Researchers have developed a tool that can predict how patients with multiple sclerosis will respond to natalizumab treatment, allowing for targeted treatments with fewer side effects. The tool uses high-content imaging and machine learning to analyze cell morphology and identify individuals who are unlikely to respond to the medication.

Liverpool scientists lead discovery of powerful new antibiotic class to tackle deadly superbugs

Researchers at the University of Liverpool have discovered a groundbreaking new class of antibiotics called Novltex, which targets lipid II in bacterial cell walls. This innovative approach offers potent and durable protection against multidrug-resistant bacteria, addressing one of the biggest challenges in modern medicine.

SourceUniversity of Liverpool·JournalJournal of Medicinal Chemistry·DateSep 18, 2025

Weight-loss drug semaglutide reduces cocaine use in rats: Suggests possible first pharmacological treatment for human cocaine dependency

Semaglutide significantly reduces cocaine-seeking behavior in rats by 26%, with a 62% drop in seeking after abstinence. This finding suggests semaglutide's potential as a treatment for human cocaine dependency, currently lacking effective pharmacological options.

SourceEuropean College of Neuropsychopharmacology·JournalEuropean Neuropsychopharmacology·TypeExperimental study·DateSep 3, 2025

Beta blockers, the standard treatment after a heart attack, may offer no benefit for heart attack patients and women can have worse outcomes

A new study published in The New England Journal of Medicine and the European Heart Journal finds that beta blockers, commonly prescribed after a heart attack, provide no clinical benefit for patients with preserved heart function. Women treated with beta blockers had a higher risk of death, heart attack, or hospitalization for heart f...

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateAug 30, 2025

Most epilepsy patients wait a year after starting treatment for seizure relief

A new study reveals that most epilepsy patients with focal epilepsy will still experience seizures for at least a year after starting treatment. The study suggests that neurologists should rethink their initial approach to antiseizure therapy, as many patients may not respond well to the first medication or regimen prescribed.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalJAMA Neurology·TypeObservational study·DateAug 25, 2025

Ketamine use in chronic pain unsupported by evidence

A new Cochrane review has found no clear evidence of benefit for ketamine in treating chronic pain conditions. The review identified an increased risk of adverse effects such as delusions and vomiting. High-quality trials are needed to determine the role of ketamine in chronic pain care.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateAug 17, 2025

New study identifies novel neural pathway to treat alcohol use disorder

A new study found that tolcapone increases activity in the prefrontal cortex during self-control tasks, associated with better behavioral control and reduced alcohol consumption. The findings suggest that medications increasing prefrontal dopamine could be a promising lead for treating alcohol use disorder.

SourceElsevier·JournalBiological Psychiatry Cognitive Neuroscience and Neuroimaging·TypeImaging analysis·DateAug 13, 2025

Going in for a close look at lung infections

A new study sampled different lung regions in cystic fibrosis patients before and after treatment with modulators, revealing that infections persisted throughout the lungs and drove inflammation. The findings suggest damage may not be the main cause of infection persistence, raising concerns about ongoing lung function deterioration.

SourceUniversity of Washington School of Medicine/UW Medicine·JournalCell Host & Microbe·TypeExperimental study·DateAug 5, 2025

Challenging popular “ancient psychedelic mysteries” theory

Researchers Dr. Sharday Mosurinjohn and Dr. Richard Ascough critique the 'psychedelic mysteries hypothesis' in a new article, arguing that it relies on circumstantial evidence rather than solid historical scholarship. They advocate for responsible curiosity and a focus on living traditions to unlock psychedelic wisdom.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalPsychedelic Medicine·TypeCommentary/editorial·DateAug 5, 2025

Pediatric investigation study identifies the optimal dose of methylprednisolone for treating severe mycoplasma pneumoniae pneumonia

Researchers conducted a randomized clinical trial to compare low- and high-dose methylprednisolone with azithromycin for treating severe Mycoplasma pneumoniae pneumonia. The study found that lower dose regimen of glucocorticoids is sufficient, equally effective, and safer than the high dose regimen.

SourcePediatric Investigation·JournalPediatric Investigation·TypeRandomized controlled/clinical trial·DateJul 31, 2025

Characterizing antibodies targeting antisense oligonucleotide modifications

Researchers validated panels of antibodies targeting clinically relevant nucleic acid modifications to visualize antisense oligonucleotides in both in vitro and in vivo studies. The tools enable detection of modified nucleic acids irrespective of sequence, facilitating multiple clinical and pre-clinical workflows.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·TypeExperimental study·DateJul 31, 2025